Strong demand fuels rapid growth at Discovery Park

Leading life science, technology and innovation campus, Discovery Park, has made a positive start to 2022 by announcing a huge increase in tenants during 2021.

Over the last 12 months, Discovery Park’s property team agreed leases with 53 new arrivals for a total of more than 46,000 sq ft of office and laboratory space at the site in East Kent.

Mayer Schreiber, Chief Executive Officer at Discovery Park, said: “Despite the Covid lockdowns with many people working from home, we finished the year on a high.

"Over the past year we saw a growing demand from innovation-based businesses, especially those in the industrial biotechnology sector, including those focused on the net zero agenda. Each new arrival is eager to work alongside like-minded entrepreneurs, as well as well-established companies with access to high quality laboratories and cluster of professional advisers.

Highlights in 2021 included the arrival of global power solutions provider Cummins, which relocated 200 staff from its former base in Thanet, taking 16,500 sq ft of office space.

Strong demand for space at Discovery Park is from businesses involved in life sciences, which collectively took more than 10,000 sq ft of laboratories to facilitate growth. One of the drivers for the growth is from businesses looking for high quality laboratory space and the lack of it in London.

Jane Kennedy, Chief Business Officer at Discovery Park, added: “Our pipeline of enquiries remains strong, with heads of terms agreed with a number of businesses. Over the next couple of months we will be announcing the arrival of companies involved in the study of viruses and zero emission transport, focused on solving some of the most important issues of our time.”

Recognising the needs of tenants to recruit and retain skilled staff, Discovery Park recently brought together the combined expertise of Canterbury Christ Church University, EKC Group, Pfizer, The Stem Hub, University of Kent and new arrival Cummins, to create the Skills Hub. It will enable tenants to offer further training to their workforce, as well as helping them find new talent to drive their businesses forward.

Eleven of the companies to make Discovery Park their home since 1 January last year were attracted by the flexible leasing and small offices in the Start Up Zone, with space for them to expand as the companies grow.

For more information about Discovery Park’s offering to businesses visit

More news and updates

BIA celebrates RQ BIO licencing agreement with AstraZeneca for monoclonal antibodies targeted at COVID-19

Today RQ BIO has announced a licencing agreement with AstraZeneca for its portfolio of early-stage monoclonal antibodies targeted against SARS-CoV-2, with the company also emerging from stealth mode on completion of the agreement. RQ Bio is a UK-based biotechnology company focused on developing treatments and preventative therapies based on potent broad-spectrum mAbs to address areas of unmet need in vulnerable patient populations.

Coulter Partners places Chief Operating Officer at Treadwell Therapeutics, playing an integral role in the company’s evolution

Coulter Partners, the global experts in Executive Search and Leadership Development in Life Sciences, Health, and Tech, recently partnered with Treadwell Therapeutics, a clinical-stage biotechnology company developing novel, cross-modality medicines for unmet needs in cancer, and are pleased to announce the placement of J.D. Mowery as Chief Operating Officer (COO).

Innovation community at The Oxford Science Park expands further as companies move into the Hayakawa Building

The innovation community at The Oxford Science Park, one of Europe's leading locations for science and technology companies, continues to expand as firms move into the newly refurbished Hayakawa Building.

BioIVT to Provide Rare Biosamples for the FNIH Biomarkers Consortium Neurodegenerative Disease Project

BioIVT is sourcing matched sets of cerebrospinal fluid, serum, and plasma from donors afflicted with ALS to further research of neurofilament in the blood as a biomarker for early stages of neurodegeneration.


More within